Appointment dossier — Ovarian Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Carcinoma
- Bevacizumab — Human evidence · 2 positive / 2 negative-mixed · PMID 38872480, 22529265, 39013199, 36603894
- Relacorilant — Human evidence · 2 positive · PMID 42334771, 40473448, 39032926
- Cisplatin — Human evidence · 1 positive / 1 negative-mixed · PMID 39549720, 39013199, 22330607
- Mirvetuximab Soravtansine — Human evidence · 1 positive / 1 negative-mixed · PMID 40508029, 30379722
- Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
- Rucaparib — Human evidence · 0 positive / 1 negative-mixed · PMID 39266137, 39013199, 34593565
- Paclitaxel — Lab evidence · 1 positive / 1 negative-mixed · PMID 38884523, 39013199, 22591426
- Anastrozole — Review evidence · 0 positive · PMID 39013199
- Carboplatin — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Olaparib — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT04851119 · Phase 1 / Phase 2 — Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (United States)
- NCT05759923 · Phase 1 — First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours (Poland)
- NCT03296826 — Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2 (Japan)
- NCT03755739 · Phase 2 / Phase 3 — Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (China)
- NCT01174121 · Phase 2 — Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (United States)
- NCT06386146 · Phase 1 / Phase 2 — JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (United States)
- NCT06771219 · Phase 1 — SLV-154 Treatment of Metastatic Solid Tumors (United States)
- NCT06666270 · Phase 1 — Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors (China)
- NCT06533332 · Phase 1 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors (Australia)
- NCT05606692 · Phase 4 — Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) (Taiwan)
- NCT06161025 · Phase 2 / Phase 3 — A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (United States)
- NCT06836128 · Phase 3 — The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients (Egypt)
- NCT06343870 · Phase 3 — Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME) (Brazil)
- NCT07023484 · Phase 2 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer (China)
- NCT07050771 · Phase 2 — Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery (United States)
- NCT06014528 · Phase 2 — IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (China)
- NCT06971744 · Phase 2 — Autophagy Maintenance (AUTOMAIN) (United States)
- NCT07371104 · Phase 1 — Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer (South Korea)
Most-relevant first: trials that name Ovarian Carcinoma, then broader trials you may still qualify for. 652 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Niraparib †Rx × Bevacizumab — Synergize (low)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Bevacizumab has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Cisplatin has been studied in people for Ovarian Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT04851119), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?